Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Continuing with Dr. Ross Camidge as our focus (see yesterday's post for a brief update from him on the afatinib/cetuximab trial), today let's turn to the recent webinar program he and Dr. Ben Solomon did with us on the subject of ALK Inhibition: From Biology to FDA-Approved Therapy for Advanced NSCLC". After Dr. Solomon provided an excellent summary of the biology and early clinical experience with XALKORI (crizotinib) that was so impressive in (the admittedly limited population of) ALK-positive patients, Dr. Camidge led us through the second part of the program. His focus was on the practical implications from here: with a newly approved therapy of XALKORI tied to a rather uncommon molecular marker, who should we be screening for it? And what are the options for these patients after they develop acquired resistance to XALKORI?
Here is the presentation by Dr. Camidge in audio and video podcast format, along with the associated transcript and figures for the program:
We'll soon have the question and answer session from this webinar program available as a podcast for you. Between now and then, I'll next be moving from Ross to a newly-identified mutation called ROS-1 and worked on largely by...wait for it...
Dr. Ross Camidge.
Special thanks to the LUNGevity Foundation for partnering with us to make this program and all of our lung cancer-related activities possible.
Please feel free to offer comments and raise questions in our
discussion forums.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.